A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma

BACKGROUND: In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable. The current clinical study was conducted to retrospectively compare the efficacy and safety of first-line paclitaxel/S-1(PS) and paclitaxel/cisplatin(TP) regimens in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai-ying, Yao, Zhi-hua, Tang, Hong, Zhao, Yan, Jin, Shui-ling, Zhou, Wen-ping, Yao, Shu-na, Yang, Shu-jun, Liu, Yan-yan, Luo, Su-xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352341/
https://www.ncbi.nlm.nih.gov/pubmed/27902478
http://dx.doi.org/10.18632/oncotarget.13602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352341/
https://www.ncbi.nlm.nih.gov/pubmed/27902478
http://dx.doi.org/10.18632/oncotarget.13602

Ejemplares similares